by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract INTRODUCTION Age-related cognitive decline and Alzheimer’s disease (AD) are strongly influenced by lipid metabolism, yet how central and peripheral lipid profiles relate to disease risk before symptom onset remains unclear. METHODS We performed...
by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract INTRODUCTION Plasma β-synuclein is a promising blood-based synaptic biomarker, but relationships with synaptic density as indicated by [11C]UCB-J positron emission tomography (PET), and blood biomarkers of Alzheimer’s disease (AD) pathology,...
by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract BACKGROUND Although lecanemab has demonstrated clinical efficacy in early Alzheimer’s disease (AD), its cost-effectiveness in China remains uncertain. This study evaluated the long-term cost-effectiveness of lecanemab in Chinese patients from a societal...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract BACKGROUND Genome-wide association studies (GWASs) identified multiple genetic variants associated with Alzheimer’s disease (AD) risk, yet the biological pathways linking these to amyloid and tau pathology remain unclear. METHODS We conducted a...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract INTRODUCTION Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD-GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people...
